IGI Logo

Aurobindo Pharma is currently trading at Rs. 1030.20, up by 12.25 points or 1.20% from its previous closing of Rs. 1017.95 on the BSE.

The scrip opened at Rs. 1030.20 and has touched a high and low of Rs. 1040.00 and Rs. 1019.00 respectively. So far 53230 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 443.15 on 14-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1040.00 and Rs. 977.25 respectively. The current market cap of the company is Rs. 59645.62 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Deflazacort Tablets, 6 mg, 18 mg, 30 mg and 36 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), EMFLAZA tablets 6 mg, 18 mg, 30 mg and 36 mg of PTC Therapeutics Inc. The product will be launched in February 2024.

The approved product has an estimated market size of $67 million for the three months ending September 2023, according to PTC Therapeutics Inc. Aurobindo now has a total of 502 ANDA approvals (482 Final approvals and 20 tentative approvals) from USFDA. Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.